Ain Holdings Inc. · TSE:9627
Ain — Q1 FY4/25 Earnings Presentation
20 slides from Ain's earnings presentation, September 2024
Slide 1: FY4/25 1Q IR Presentation
FY4/25 1Q IR PRESENTATION September 2024
Slide 2: Results Overview
Results Overview © AIN HOLDINGS INC. All Rights Reserved. 1
Slide 3: Consolidated P/L
Consolidated P/L Net sales increased 9.5% YoY and 5.9% against the plan due to contribution of stores opened in the previous year and growth at existing stores in both businesses. Ordinary profit decreased 23.5% YoY and increased 12.8% against the plan. FY4/24 1Q FY4/25 1Q FY4/25 1Q YoY YoY Vs （¥ mi
Slide 4: Dispensing Pharmacy Business (Consolidated)
Dispensing Pharmacy Business (Consolidated) Net sales increased 8.8% YoY and 6.0% against the plan because the average prescription price of existing stores and stores opened in the previous year rose due to an increase in high-cost. Segment profit decreased 21.8% YoY and 0.6% against the plan becau
Slide 5: Cosmetic and Drug Store Business (Consolidated)
Cosmetic and Drug Store Business (Consolidated) Net sales up 20.7% YoY and 7.9% against the plan because unit prices per customers increased due to growth in sales of Asian cosmetics, etc., maintaining the trend from the previous fiscal year. Segment profit increased 43.1% YoY and 22.4% against the
Slide 6: Consolidated B/S
Consolidated B/S Net cash became ¥43,239 million and shareholders’ equity ratio became 54.1%. We are maintaining a sound financial structure. End-FY4/24 (¥ million) End-FY4/25 1Q (¥ million) Assets Liabilities and Net Assets Assets Liabilities and Net Assets Current Current Current assets 110,743 li
Slide 7: Assets
Assets The balance of total assets decreased ¥1,270 million from the end of the previous fiscal year because of increase in inventories due to decrease in accounts receivable – trade and goodwill, etc. (¥ million) End-FY4/24 1Q End-FY4/24 End-FY4/25 1Q Change Cash and deposits 47,373 48,611 49,404 +
Slide 8: Liabilities and Net Assets
Liabilities and Net Assets Accounts payable – trade increased ¥4,978 million due to M&A and new store openings. Short- term and long-term borrowings decreased ¥830 million. (¥ million) End-FY4/24 1Q End-FY4/24 End-FY4/25 1Q Change Accounts payable – trade 64,859 65,506 70,484 +4,978 Short-term borro
Slide 9: Review
Review © AIN HOLDINGS INC. All Rights Reserved. 8
Slide 10: Consolidated (YoY results)
Consolidated (YoY results) Ordinary profit decreased ¥0.9 billion YoY due to the effect of dispensing fee revisions in dispensing pharmacy business, etc. Net sales Ordinary profit ¥94.6 billion ¥103.6 billion +¥9.0 billion ¥3.8 billion ¥2.9 billion ¥(0.9) billion +9.5% (23.5)% ■Dispensing Dispensing
Slide 11: Consolidated (vs Plan)
Consolidated (vs Plan) Ordinary profit increased ¥0.3 billion against the plan due to increase in sales along with unit prices per customers increase in the cosmetic and drug store business. Net sales Ordinary profit ¥97.8 billion ¥103.6 billion +¥5.8 billion ¥2.6 billion ¥2.9 billion ＋¥0.3 billion
Slide 12: Number of Pharmacies and Stores
Number of Pharmacies and Stores ■ Plan and Results FY4/25 1Q FY4/25 Plan Results Plan Dispensing Pharmacy 11 12 80 Organic 6 6 40 Opening M&A 5 6 40 Cosmetic and drug store 2 2 10 Total 13 14 90 Dispensing Pharmacy 8 8 16 Closure Cosmetic and drug store 0 1 2 Total 8 9 18 ■ Transition of dispensing
Slide 13: Revised Plan
Revised Plan © AIN HOLDINGS INC. All Rights Reserved. 12
Slide 14: FY4/25 Plan (Dispensing Pharmacy Business)
FY4/25 Plan (Dispensing Pharmacy Business) The group forecasts net sales increase 6.3% YoY and 2.8% against the initial plan, and segment profit decrease 8.3% YoY and increase 1.0% against the initial plan as the average prescription price rose due to an increase in high-cost prescriptions. FY4/24 F
Slide 15: FY4/25 Plan (Cosmetic and Drug Store Business)
FY4/25 Plan (Cosmetic and Drug Store Business) The group forecasts net sales increase 97.0% YoY and 84.4% against the initial plan, and segment profit increase 52.5% YoY and 38.8% against the initial plan due to the addition of Francfranc Corporation to the Group and steady sales growth of AINZ & TU
Slide 16: FY4/25 Plan (Consolidated)
FY4/25 Plan (Consolidated) The group forecasts net sales for the fiscal year ending April 30, 2025 increase 13.4% YoY and 9.3% against the initial plan, and ordinary profit will decrease 6.4% YoY and increase 8.1% against the initial plan due to the revision of both businesses plans. FY4/24 FY4/25 F
Slide 17: Revised plan (YoY results)
Revised plan (YoY results) The group forecasts net sales increase ¥53.7 billion and ordinary profit will decrease ¥1.3 billion YoY. Net sales Ordinary profit ¥399.8 billion ¥453.5 billion+¥53.7 billion ¥21.3 billion ¥20.0 billion ¥(1.3) billion +13.4% (6.4)% ■Dispensing ■Dispensing pharmacy pharmacy
Slide 18: Revised plan (vs Initial Plan)
Revised plan (vs Initial Plan) The group forecasts net sales increase ¥38.5 billion and ordinary profit increase ¥1.5 billion against the initial plan. Net sales Ordinary profit ¥415.0 billion ¥453.5 billion +¥38.5 billion ¥18.5 billion ¥20.0 billion +¥1.5 billion +9.3% +8.1% ■Dispensing ■Dispensing
Slide 19: AIN HOLDINGS INC. Corporate Planning Division
Inquiries related to this presentation should be addressed to AIN HOLDINGS INC. Corporate Planning Division TEL: +81-3-5333-1812 https://www.ainj.co.jp/corporate/ This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been
Slide 20: AIN GROUP
AIN GROUP